TOP > 外国特許検索 > BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME

BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME NEW 新技術説明会

外国特許コード F170008962
整理番号 E112P06WO
掲載日 2017年3月13日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP070317
国際公開番号 WO 2016010092
国際出願日 平成27年7月15日(2015.7.15)
国際公開日 平成28年1月21日(2016.1.21)
優先権データ
  • 特願2014-145736 (2014.7.16) JP
発明の名称 (英語) BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME NEW 新技術説明会
発明の概要(英語) Provided are: a compound that is useful as an amyloid oxidation catalyst which can be applied inside a living body and can be applied not only to Aβ peptides but also to other amyloids; and an amyloid-related preventive or therapeutic drug using said compound. A benzothiazole compound which is represented by general formula (1) (in the formula, X represents a halogen atom; R1 represents a hydrocarbon group which may have a substituent; R2 represents a hydrogen atom or a hydrocarbon group which may have a substituent; R3 and R4 are the same or different and represent a hydrogen atom, an alkoxy group, a halogen atom, an amino group, a nitro group, a cyano group, or a hydrocarbon group which may have a substituent; R2 and R4 together may form an alkylene group, and R5 represents an anion).
特許請求の範囲(英語) [claim1]
1. The next general formula (1)
(In formula, as for X showing halogen atom;
As for R (1), showing the hydrocarbon radical which is possible to have possessed the substituent;
As for R (2) showing the hydrocarbon radical which is possible to have possessed the hydrogen atom, or the substituent;
R (3) and R as for (4), equality or differing, the hydrogen atom, the hydrocarbon radical which is possible to have possessed the substituent, alkoxy group and the halogen atom, the amino group, showing the nitro group or the cyano basis;
R (2) and, R (4) becoming simultaneous, may form the alkylene basis,
R (5) shows the anion)
So the benzo thiazole compound which is displayed.
[claim2]
2. R (1), R (2), R (3) and in R (4) the basis which it can substitute in the hydrocarbon radical differing, equality or, the halogen atom, the amino group, the nitro group and the cyano basis, the 1-3 which is chosen from alkoxy group, the acyl basis, the carboxyl group, the alkoxy carbonyl group, the aromatic hydrocarbon radical and the complex cyclic basis the benzo thiazole compound of the claim 1 statement which is.
[claim3]
3. R (1), the claim the benzo thiazole compound of 1 which is the alkyl or the [arukeniru] basis of the carbon count 1-12 or 2 statements.
[claim4]
4. R (1), either of the claim 1-3 which is the alkyl group of the carbon count 1-12 in 1 sections the benzo thiazole compound of statement.
[claim5]
5. R (3), either of the claim 1-4 which is the hydrogen atom or the alkyl or the [arukeniru] basis of the carbon count 1-12 in 1 sections the benzo thiazole compound of statement.
[claim6]
6. R (3), in either of the claim 1-5 which is the hydrogen atom the benzo thiazole compound of statement.
[claim7]
7. R (2), R (4) and becoming simultaneous, C [2] - C [4] alkylene basis is formed, or or the alkyl or the [arukeniru] basis of the carbon count 1-12 (, the carboxyl group and the alkoxy carbonyl group, amino - the CO basis or dipeptide - hexa- peptide - [CO]- substitutes in this alkyl or the [arukeniru] basis, this amino acid, furthermore the 1-2 which is chosen from C [6-14] aryl basis and the alkoxy carbonyl group to dipeptide - hexa- peptide has been allowed to have substituted.)So either of the claim 1-6 which is in 1 sections the benzo thiazole compound of statement.
[claim8]
8. In either of the claim 1-7 the medicine which designates the benzo thiazole compound of statement as the active ingredient in 1 sections.
[claim9]
9. The medicine of the claim 8 statement which is the preventive of the disease where the pathogenic amyloid participates or remedy.
[claim10]
10. Either of the claim 1-7 the medicine composition which contains the benzo thiazole compound of statement and the carrier which is allowed pharmacy in 1 sections.
[claim11]
11. Either of the claim 1-7 in order to use for the prevention or remedy of the disease where the pathogenic amyloid participates in 1 sections the chemical compound of statement.
[claim12]
12. Prevention of the disease where the pathogenic amyloid participates or either of the claim 1-7 for remedy production in 1 sections use of the chemical compound of statement.
[claim13]
13. Either of the claim 1-7 preventive of the disease where the pathogenic amyloid which features that the chemical compound of statement is prescribed to 1 sections participates or remedy method.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • KANAI MOTOMU
  • SOMA YOHEI
  • TANIGUCHI ATSUHIKO
  • SHIMIZU YUSUKE
国際特許分類(IPC)
指定国 (WO201610092)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) ERATO KANAI Life Science Catalysis AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close